Gilead Reached USD 455 Mn Contract with Everest for Asian Rights

Healthcare Author: Fuller Wang, Fierce Pharma Aug 16, 2022 05:47 PM (GMT+8)

The company said it would use the money to fund additional dealmaking activities, clinical development of Calliditas Therapeutics-partnered kidney disease drug Nefecon in several Asia countries and other pipeline assets.

Online healthcare

On August 15, 2022, Gilead is shelling out USD 280 million upfront to gain Trodelvy rights from Chinese company Everest Medicines in certain Asian territories, including China, South Korea, Singapore and others. Everest could also receive up to USD 175 million in potential regulatory and commercial milestone payments down the line. For Gilead, the deal allows the California biotech to take full control of Trodelvy, a cornerstone of the company’s portfolio in solid tumors. Meanwhile, Gilead will have the opportunity to recruit some Everest employees who have been working on Trodelvy

Catalent's Carla Vozone discusses the significant trends in the Orally Inhaled & Nasal Drug Delivery (OINDP) segment, including larger molecules and novel indications. She also discusses changes within CDMOs and various challenges facing the industry. Download the e-book to learn more. The news comes just two months after Everest won a Trodelvy nod in China for triple-negative breast cancer (TNBC) following at least two prior systemic therapies, including at least one for metastatic disease. It marked both Trodelvy’s and Everest’s first approval in China. At that time, Everest said it planned to launch the drug in the fourth quarter.

The deal is regarded as a short-term relief for Everest by many analysts. The company said it would use the money to fund additional dealmaking activities, clinical development of Calliditas Therapeutics-partnered kidney disease drug Nefecon in several Asia countries and other pipeline assets.